Comparison of Cellular Characteristics between Human Hepatoma Cell Lines with Wild-Type p53 and Those with Mutant-Type p53 Gene

Acta Medica Okayama

Volumn 51, Issue 6, 1997, Pages 313-319

  Pu, Hong ^a   Tsuji, Toshiya ^a   Kondo, Asami ^a   Fushimi, Kazuo ^a   Ohashi, Ryuichiro ^a   Inoue, Yusuke ^a   Mimura, Tetsushige ^b   Hamazaki, Keisuke ^c   Miyazaki, Masahiro ^a   Namba, Masayoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c University of Tokyo   (Japan)

Author keywords

Hepatoma; p16; p21; p27; p53; Rb; TNF

Indexed keywords

ANIMAL; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GENES, P53; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MUTATION; TUMOR CELLS, CULTURED;

EID: 0031306070     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 54, 4855-4878.
2. Harris CC: p53 Tumor suppressor gene: From the basic research laboratory to the clinic: An abridged historical perspective. Carcinogenesis (1996) 17, 1187-1198.
3. Sherr CJ: Cancer cell cycles. Science (1996) 274, 1672-1677.
4. Mihara K, Miyazaki M, Kondo T, Fushimi K, Tsuji T, Inoue Y, Fukaya K, Ishioka C and Namba M: Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory. Acta Med Okayama (1997) 261-265.
5. Homma S: Studies on the establishment and some biological characteristics of cultured human liver cancer cell lines: Their growth, functional and morphological characteristics and temperature sensitivities. Jikeikai Med J (1985) 32, 289-315.
6. Doi I, Namba M and Sato J: Establishment and some characteristics of human hepatoma cell lines. Gann (1975) 66, 385-392.
7. Nakabayashi H, Taketa K, Miyano K, Yamane T and Sato J: Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res (1982) 42, 3858-3863.
8. Alexander JJ, Bey EM, Geddes EW and Lecatsas G: Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J (1976) 50, 2124-2128.
9. Doi I: Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann (1976) 67, 1-10.
10. Aden DP, Fogel A, Plotkin S, Damjanov I and Knowles BB: Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (1979) 282, 615-616.
11. Mihara K, Cao XR, Yen A, Chandlers, Driscoll B, Murphree AL, T'ang A and Fung YK: Cell-cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science (Washington DC) (1989) 246, 1300-1303.
12. Fushimi K, Torigoe K, Yamauchi H, Kurimoto M and Namba M: Establishment of a human fibroblast cell line producing tumor necrosis factor α (KMST-6/TNF-α) and growth inhibitory effects of its conditioned medium on malignant cells in culture. In Vitro Cell Dev Biol (1997) (in press).
13. Mulder JW, Offerhaus GJ, Vogelstein B and Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol (1994) 172, 5-12.
14. Perry ME and Levine AJ: Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev (1993) 3, 50-54.
15. El-Deiry WS, Tokino T, Velculecsu VE, Devy DB, Persons R, Trent JM, Lin D, Wercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75, 817-825.
16. Harper JW, Adami GR, Wei N, Keyomarsi K and Effedge SJ: The p21 cdk-interacting protein Cip I is a potent inhibitor of G1 cyclin-dependent-kinase. Cell (1993) 75, 805-816.
17. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature (1993) 366, 701-704.
18. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 366, 704-707.
19. Xiong Y, Zhang H and Beach D: Subunit rearrangement of the cyclin dependent kinases is associated with cellular transformation. Genes Develop (1993) 7, 1572-1583.
20. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 78, 59-66.
21. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk4 protein kinase activity, is related to p21. Cell (1994) 78, 67-74.
22. Hayflick L and Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res (1961) 25, 585-621.
23. Hartwell LH: Defects in a cell cycle checkpoint may be responsible for the nenomin instability of cancer cells. Cell (1992) 71, 1821-1828.
24. Herrera RE, Mäkelä TP and Weinberg RA: TGFβ-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol Biol Cell (1996) 7, 1335-1342.
25. Goossens V, Grooten J, de Vos K and Fiers W: Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci (1995) 92, 8112-8119.
26. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell (1992) 70, 923-935.
27. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 70, 937-948.
28. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 51, 6304-6311.
29. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A and Harris CC: Integrity of p53 in hepatitis Bx antigen-positive and -negative hepatocellular carcinomas. Cancer Res (1997) 57, 426-432.